Drugs / Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04083183 | Jun 2020 → Jan 2028 expected | benign neoplasm | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04083183 ↗ |
| Modality | Monoclonal antibody | “Astatine-211-labeled BC8-B10 monoclonal antibody is a monoclonal antibody” NCT04083183 ↗ |
| Route | Intravenous | “Given IV” NCT04083183 ↗ |